[go: up one dir, main page]

BRPI0701016A2 - molÉculas com atividade analgÉsica, sedativa e adjuvante de anestÉsicos - Google Patents

molÉculas com atividade analgÉsica, sedativa e adjuvante de anestÉsicos

Info

Publication number
BRPI0701016A2
BRPI0701016A2 BRPI0701016-8A BRPI0701016A BRPI0701016A2 BR PI0701016 A2 BRPI0701016 A2 BR PI0701016A2 BR PI0701016 A BRPI0701016 A BR PI0701016A BR PI0701016 A2 BRPI0701016 A2 BR PI0701016A2
Authority
BR
Brazil
Prior art keywords
sedative
analgesic
molecules
anesthetics
adjuvant activity
Prior art date
Application number
BRPI0701016-8A
Other languages
English (en)
Inventor
Rocha Pitta Ivan Da
Original Assignee
Univ Fed Pernambuco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fed Pernambuco filed Critical Univ Fed Pernambuco
Priority to BRPI0701016-8A priority Critical patent/BRPI0701016B1/pt
Priority to PCT/BR2008/000145 priority patent/WO2008134840A2/en
Priority to US12/598,347 priority patent/US8217068B2/en
Priority to EP08748070A priority patent/EP2167475A2/en
Priority to BRPI0810737-8A2A priority patent/BRPI0810737A2/pt
Publication of BRPI0701016A2 publication Critical patent/BRPI0701016A2/pt
Publication of BRPI0701016B1 publication Critical patent/BRPI0701016B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MOLÉCULAS COM ATIVIDADE ANALGÉSICA, SEDATIVA E ADJUVANTE DE ANESTÉSICOS. A presente invenção é relativa a uma nova série de substancias da série 3-benzil-imidazolidina-2,4-diona substituida nas posições orto do anel benzílico por halogênios como exemplificado para a molécula codificada LPSF-PT-31, 3-(2-cloro-6-fluor- benzil)-imidazolidina-2,4-diona, GIRSIJPAN e seu uso terapêutico enquanto fármacos dotados de efeitos analgésico, sedativo e adjuvante de anestésicos.
BRPI0701016-8A 2007-05-03 2007-05-03 Moléculas com atividade analgésica, sedativa e adjuvante de anestésicos BRPI0701016B1 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0701016-8A BRPI0701016B1 (pt) 2007-05-03 2007-05-03 Moléculas com atividade analgésica, sedativa e adjuvante de anestésicos
PCT/BR2008/000145 WO2008134840A2 (en) 2007-05-03 2008-05-05 Compound with anesthetics activity, methods for its production an pharmaceutical compositions comprising the same
US12/598,347 US8217068B2 (en) 2007-05-03 2008-05-05 Compound with anesthetics activity, methods for its production and pharmaceutical compositions comprising the same
EP08748070A EP2167475A2 (en) 2007-05-03 2008-05-05 Compound with anesthetics activity, methods for its production an pharmaceutical compositions comprising the same
BRPI0810737-8A2A BRPI0810737A2 (pt) 2007-05-03 2008-05-05 Composto com atividade analgésica, processo de produção e composição farmacêutica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0701016-8A BRPI0701016B1 (pt) 2007-05-03 2007-05-03 Moléculas com atividade analgésica, sedativa e adjuvante de anestésicos

Publications (2)

Publication Number Publication Date
BRPI0701016A2 true BRPI0701016A2 (pt) 2008-12-16
BRPI0701016B1 BRPI0701016B1 (pt) 2021-10-26

Family

ID=39944056

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0701016-8A BRPI0701016B1 (pt) 2007-05-03 2007-05-03 Moléculas com atividade analgésica, sedativa e adjuvante de anestésicos
BRPI0810737-8A2A BRPI0810737A2 (pt) 2007-05-03 2008-05-05 Composto com atividade analgésica, processo de produção e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0810737-8A2A BRPI0810737A2 (pt) 2007-05-03 2008-05-05 Composto com atividade analgésica, processo de produção e composição farmacêutica

Country Status (4)

Country Link
US (1) US8217068B2 (pt)
EP (1) EP2167475A2 (pt)
BR (2) BRPI0701016B1 (pt)
WO (1) WO2008134840A2 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759002A (en) * 1954-03-24 1956-08-14 Abbott Lab 3-benzyl hydantoin and process
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
GB2386892A (en) 2002-03-28 2003-10-01 Pantherix Ltd Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
KR20050026023A (ko) 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. 아릴 치환된 히단토인 화합물 및 그들의 나트륨 채널차단제로서의 용도

Also Published As

Publication number Publication date
EP2167475A2 (en) 2010-03-31
WO2008134840A3 (en) 2009-01-29
BRPI0810737A2 (pt) 2014-10-21
WO2008134840A2 (en) 2008-11-13
US20100130575A1 (en) 2010-05-27
US8217068B2 (en) 2012-07-10
BRPI0701016B1 (pt) 2021-10-26

Similar Documents

Publication Publication Date Title
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2008003822A1 (es) Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer.
UY32094A (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
DK3045474T3 (da) Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation
BR112012011403A2 (pt) composição farmacêutica compreendendo um agonista glp-1 e metionina
PA8740901A1 (es) Compuestos organicos
CO6511228A2 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
UY31053A1 (es) Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso
CL2008000915A1 (es) Compuestos triciclicos moduladores de 11beta-hidroxiesteroidedeshidrogenasa tipo 1; y uso en el tratamiento, prevencion y/o profilaxis de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, hipertension y obesidad.
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2008002560A1 (es) Compuestos derivados de n-benzamida sustituidos; inhibidores de la via de señalizacion hedgehog; composicion farmaceutica, utiles para el tratamiento de enfermedades en que es necesaria la reduccion de la proliferacion y diferenciacion celular y/o afectar la modulacion del microambiente estromal, tales como cancer y psoriasis.
CL2008001612A1 (es) 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
CL2008000180A1 (es) Sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como depresion, trastornos del sueno, ansiedad y enfermedades del tracto
DOP2009000196A (es) Inhibidores de la actividad de akt
MX2012007548A (es) Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos.
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1980 DE 16/12/2008, QUANTO AO ITEM (72).

B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2460 DE 27/02/2018

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15V Prolongation of time limit allowed

Free format text: REFERENTE A PETICAO NO 870180129618 DE 13/09/2018 - RECONHECIDA A JUSTA CAUSA, DE ACORDO COM O ARTIGO 221 DA LPI 9279/96 E O ARTIGO 2O DA RESOLUCAO 178/2017, SERA CONCEDIDO O PRAZO ADICIONAL DE 15 (QUINZE) DIAS, CONTADOS A PARTIR DA DATA DESTA PUBLICACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.11 NA RPI NO 2489 DE 18/09/2018.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.